Serine protease inhibitor A3 is a soluble SIRPα ligand that suppresses inflammation and antitumor immunity.

作者信息Yufei Hou, Lei Huang, Chunhui Jin, Xiaolong Li, Yongxing Chen, Liguang Sun, Feng Wang, Yong Zhang, Ying Wang, Meijuan Zou, Qina Xu, Zicheng Wang, Tao Jin, Naicui Zhai, Fei Xu, Wentao Liu, Yong-Guang Yang
PMID42918845
发布时间2026-11
DOI10.1038/s41590-026-02682-5

摘要

SIRPα is an inhibitory receptor with the canonical ligand CD47. Here, we show that human serine protease inhibitor A3 (SERPINA3) and its mouse ortholog SERPINA3k function as soluble binders and activators of SIRPα, suppressing SIRPα+ macrophages, neutrophils, dendritic cells and natural killer cells. SERPINA3(k) treatment alleviates lipopolysaccharide-induced pneumonia and ameliorates experimental autoimmune encephalomyelitis and rheumatoid arthritis. Although wild-type SERPINA3 provokes inflammation in cardiomyocytes and brain vascular endothelial cells, the SERPINA3D2 mutant, identified through functional domain mapping for SIRPα interaction, abolishes these adverse effects while retaining full inhibitory capacity. Notably, cancer cells secrete large amounts of SERPINA3(k), exceeding CD47 levels. Anti-SERPINA3(k) antibodies, used alone or in combination with blockade of programmed cell death 1 receptor/programmed cell death ligand 1, inhibit tumor growth in multiple preclinical models. This work identifies a potent soluble SIRPα ligand, offering effective therapeutic strategies for inflammatory/autoimmune diseases and a promising target for cancer immunotherapy.